diazoxide has been researched along with Polycystic Ovarian Syndrome in 16 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS)." | 9.16 | A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. ( Bachmann, LM; Cheang, KI; Downs, RW; Nestler, JE; Reilly, ER, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 9.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| "To test the hypothesis that insulin plays a role in the hyperandrogenism of obese women with polycystic ovary syndrome, we conducted a prospective study in which the androgen status of five obese women with polycystic ovary syndrome was assessed on two occasions: before and after 10 days of oral diazoxide (100 mg, three times daily) administration." | 7.67 | Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. ( Barlascini, CO; Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Steingold, KA, 1989) |
| "Diazoxide 300 mg daily was given to all women starting after the end of the OGTT for 10 days." | 5.30 | Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide. ( Blum, W; Jacobs, H; Kaltsas, TT; Krassas, GE; Messinis, I; Pontikides, N, 1998) |
| "We conducted a pilot project to test the hypothesis that decreasing insulin concentrations with diazoxide would affect parameters of vitamin D in obese women with and without polycystic ovary syndrome (PCOS)." | 5.16 | A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome. ( Bachmann, LM; Cheang, KI; Downs, RW; Nestler, JE; Reilly, ER, 2012) |
| "Obese women with polycystic ovary syndrome (PCOS) manifest impaired insulin-stimulated release of a d-chiro-inositol-containing inositolphosphoglycan (DCI-IPG) insulin mediator during oral glucose tolerance testing (OGTT), which appears to be restored by the administration of metformin." | 5.14 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Iuorno, MJ; Nestler, JE, 2010) |
| "Suppression of serum insulin levels with diazoxide is associated with a decrease in serum testosterone and an increase in serum sex hormone-binding globulin in obese women with the polycystic ovary syndrome." | 5.06 | Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. ( Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Singh, R, 1990) |
| "The suppression of hyperinsulinism with diazoxide (300 mg/d during 30 days) in a young woman with PCOS and hirsutism, hyperinsulinism and insulinoresistance was followed by a modification of plasma androgens." | 3.69 | [Polycystic ovary and diazoxide. In vivo study]. ( Bercovici, JP; Brettes, JP; Floch, HH; Monguillon, P; Nahoul, K, 1996) |
| "To test the hypothesis that insulin plays a role in the hyperandrogenism of obese women with polycystic ovary syndrome, we conducted a prospective study in which the androgen status of five obese women with polycystic ovary syndrome was assessed on two occasions: before and after 10 days of oral diazoxide (100 mg, three times daily) administration." | 3.67 | Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. ( Barlascini, CO; Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Steingold, KA, 1989) |
| "Diazoxide 300 mg daily was given to all women starting after the end of the OGTT for 10 days." | 1.30 | Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide. ( Blum, W; Jacobs, H; Kaltsas, TT; Krassas, GE; Messinis, I; Pontikides, N, 1998) |
| "Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min." | 1.28 | A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. ( Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Powers, LP; Rittmaster, RS; Steingold, KA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baillargeon, JP | 2 |
| Iuorno, MJ | 1 |
| Apridonidze, T | 1 |
| Nestler, JE | 7 |
| Reilly, ER | 1 |
| Cheang, KI | 1 |
| Bachmann, LM | 1 |
| Downs, RW | 1 |
| Welt, CK | 1 |
| Taylor, AE | 3 |
| Martin, KA | 1 |
| Hall, JE | 1 |
| Hansen, JB | 1 |
| Evans, WS | 1 |
| Boyd, DG | 1 |
| Johnson, ML | 1 |
| Matt, DW | 4 |
| Jimenez, Y | 1 |
| Carpentier, A | 1 |
| Kassi, EN | 1 |
| Diamanti-Kandarakis, E | 1 |
| Papavassiliou, AG | 1 |
| Bercovici, JP | 1 |
| Monguillon, P | 1 |
| Nahoul, K | 1 |
| Floch, HH | 1 |
| Brettes, JP | 1 |
| van Montfrans, JM | 1 |
| van Hooff, MH | 1 |
| Hompes, PG | 1 |
| Lambalk, CB | 1 |
| Krassas, GE | 1 |
| Kaltsas, TT | 1 |
| Pontikides, N | 1 |
| Jacobs, H | 1 |
| Blum, W | 1 |
| Messinis, I | 1 |
| Powers, LP | 1 |
| Steingold, KA | 2 |
| Plymate, SR | 2 |
| Rittmaster, RS | 1 |
| Clore, JN | 3 |
| Blackard, WG | 3 |
| Singh, R | 1 |
| Barlascini, CO | 1 |
| Leng, JJ | 1 |
| Greenblatt, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is There An Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?[NCT02803476] | 166 participants (Anticipated) | Observational | 2016-03-31 | Recruiting | |||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for diazoxide and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives.
Topics: Amides; Animals; ATP-Binding Cassette Transporters; Benzopyrans; Benzothiadiazines; Congenital Hyper | 2006 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
4 trials available for diazoxide and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Cross-Sectional Studies; Diazoxide; Female; Glucose Clamp T | 2010 |
A pilot study: effects of decreasing serum insulin with diazoxide on vitamin D levels in obese women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgens; Blood Glucose; Body Weight; Comorbidity; Diazoxide; Dose-Res | 2012 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Diazoxide; Female; Follicular Phase; Humans; | 1990 |
9 other studies available for diazoxide and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone.
Topics: Adolescent; Adult; Body Mass Index; Chorionic Gonadotropin; Diazoxide; Female; Gonadotropins; Humans | 2002 |
Lack of effect of short-term diazoxide administration on luteinizing hormone secretion in women with polycystic ovary syndrome.
Topics: Adult; Cohort Studies; Diazoxide; Female; Humans; Insulin; Insulin Secretion; Luteinizing Hormone; P | 2007 |
Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity.
Topics: Adolescent; Adult; Androgens; Androstenedione; Diazoxide; Female; Humans; Insulin; Leuprolide; Lutei | 2007 |
Correlates between hyperinsulinism and hyperandrogenemia?
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Adenosine Triphosphate; Aldo-Keto | 2008 |
[Polycystic ovary and diazoxide. In vivo study].
Topics: Adolescent; Androgens; Dehydroepiandrosterone; Diazoxide; Female; Hirsutism; Humans; Hyperinsulinism | 1996 |
Leptin levels in women with polycystic ovary syndrome before and after treatment with diazoxide.
Topics: Adipose Tissue; Administration, Oral; Adult; Diazoxide; Drug Administration Schedule; Female; Humans | 1998 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
Topics: Blood Glucose; Diazoxide; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Huma | 1989 |
Hirsutism in adolescent girls.
Topics: Adolescent; Adrenocortical Hyperfunction; Cobalt; Cortisone; Cushing Syndrome; Dexamethasone; Diazox | 1972 |